74 results about "Atenolol" patented technology

The invention discloses a compound apigenin nanoemulsion antihypertensive drug which comprises the following raw materials in mass percent: 1-15% of apigenin, 5-35% of surfactant, 1-20% of cosurfactant, 1-20% of oil, 0.5-10% of motherwort fruit aqueous extract, 0.5-10% of semen cassiae water extract and the balance of distilled water; and the sum of mass percents of the above raw materials is 100%. The nanoemulsion is small in emulsion droplet, uniform in distribution, low in viscosity and good in liquidity. After apigenin is prepared into a nanoemulsion, blood brain barrier transmission capacity is obviously increased, the bioavailability of a technical material is obviously improved, the half-life period of the drug can be prolonged; and the drug administration times can be reduced; with adoption of the nanoemulsion, the dissolution and infiltration capacity of atenolol can be improved and the stability of apigenin is increased; and the nanoemulsion has obvious synergistic effect compounded with the motherwort fruit and the semen cassiae; and the medicinal cure effect can be more fully played.

The present invention relates to compound slow-release Atenolol-Nifedipine preparation and its medical application. The compound delayed preparation has active components Atenolol and Nifedipine anddelaying material for delayed release. The preparation includes also pharmacologically acceptable carrier.

The invention relates to the pharmaceutical preparation field, in particular to a compound controlled release pellet tablet of nifedipine and atenolol, and is characterized in that: controlled release pellet of nifedipine, controlled release pellet of atenolol and blank pellet are pelletized to obtain the compound controlled release pellet tablet of nifedipine and atenolol, wherein the controlled release pellet of nifedipine and the controlled release pellet of atenolol are respectively obtained from drug contained core coated with acrylic resin; the weight of coating of the controlled release pellet of nifedipine is added by 10 to 30 percent while the weight of coating of the controlled release pellet of atenolol by 8 to 25 percent; the blank pellet comprises microcrystaline cellulose and one of macrogol 6000, macrogol 4000 and stearic acid or the mixture of one or two of the macrogol 6000, the macrogol 4000 and the stearic acid, wherein the blank pellet takes up 50 to 70 percent of the total weight of the compound controlled release pellet tablet of nifedipine and atenolol.

The invention relates to a timolol long-acting transdermal preparation, the preparation process of which comprises: first preparing timolol into timolol nano-medicine or timolol micropowder, and then preparing timolol nano-medicine Or timolol micropowder is prepared into timolol hydrogel transdermal preparation, ointment transdermal preparation or microneedle transdermal preparation. The present invention also relates to the application of the above-mentioned medicine in the treatment of hemangioma. Using the medicine of the invention to treat infantile hemangioma can promote the efficiency of diseased cells to absorb medicine, improve the treatment effect, reduce the dosage of medicine, and have no adverse reaction in the treatment process.

The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine and HIF alpha protein fused to a carrier peptide.

A slow-release tablet of compound atenolol is prepared through preparing fast-release particle from atenolol and less nifedipine, preparing its slow-release layer from hydrophilic gel PEG6000, rest of nifedipine and slow-release material, and die pressing.

The invention relates to a therapeutic drug for treating arrhythmia, angina and mild and moderate hypertension as well as the preparation method thereof. The therapeutic drug aims to supplement the deficiency of the prior art and provide a sustained-release atenolol dropping pill formulation. The sustained-release atenolol dropping pill is prepared by adding stabilize Vitamin E and a hydrophobic base to the ingredients accepted in the prior art, thereby effectively overcoming the defects in the prior art and guaranteeing no occurrence of an obvious change related to the substance content for the drug during the effective storage period and has the advantages of full release, controllable release time, low frequency of drug taking, long effective hours and high bioavailability simultaneously. The sustained-release atenolol dropping pill is suitable for clinical and family use.

The invention relates to a beta-receptor blocker detection reagent and preparation and detection methods thereof, and specifically relates to a beta-receptor blocker homogeneous enzyme immunoassay reagent and preparation and detection methods thereof. The beta-receptor blocker homogeneous enzyme immunoassay reagent comprises an anti-beta-receptor blocker specific antibody, and an indication reagent for detecting an anti-beta-receptor blocker specific antibody-beta-receptor blocker compound; the anti-beta-receptor blocker specific antibody is obtained from a pindolol immunogen immune animal. The beta-receptor blocker detection reagent has the following beneficial effects: the pindolol immunogen is strong in specificity and high in immunogenicity, the prepared antibody is the anti-beta-receptor blocker specific antibody which can be specially bonded with various common beta-receptor blockers such as pindolol, bisoprolol, atenolol, metoprolol and propranolol, is strong in specificity and high in titer, and has no cross reaction with common 62 drugs; the homogeneous enzyme immunoassay reagent containing the anti-beta-receptor blocker specific antibody is capable of determining the content of various beta-receptor blockers in a sample conveniently, quickly and accurately; besides, a plurality of samples can be measured simultaneously on a full-automatic biochemical analyzer, and high-flux fast measurement of the beta-receptor blockers can be realized; the homogeneous enzyme immunoassay reagent is high in accuracy and strong in specificity, and are greatly improved in accuracy and detection efficiency in contrast with other methods.

The invention relates to the pharmaceutic preparation field and in particular relates to atenolol pH independent sustained-release tablets and a preparation method thereof. The atenolol pH independent sustained-release tablets are characterized by being prepared through the steps of evenly mixing a prescription amount of atenolol, HPMC (Hydroxy propyl methyl cellulose) K15M, eudragit RSPO, high-viscosity PEO (Polyethylene Oxide) and lactose monohydrate in such a manner of progressively increasing by equal amount, next, adding a small quantity of magnesium stearate and aerosil as the lubricant, and then forming the atenolol pH independent sustained-release tablets through a powder vertical-compression process. The pH independent sustained-release tablets are prepared effectively, and the slightly alkaline drug atenolol is provided to have similar release characteristic under different simulated gastrointestinal tract pH conditions. The HPMC stable in slow release performance is taken as the slow release framework of the pH independent sustained-release tablets, the eudragit RSPO is taken as the pH regulator of the pH independent sustained-release tablets, and the high-viscosity PEO is taken as the retardant of the pH independent sustained-release tablets; the preparation process is simple, the adverse effect of the drug is remarkably reduced and the compliance of the patient is improved; and besides, the pH independent sustained-release tablets have important economic value and social significance.

The invention relates to the pharmaceutical preparation field, in particular to a compound controlled release pellet tablet of nifedipine and atenolol, and is characterized in that: controlled release pellet of nifedipine, controlled release pellet of atenolol and blank pellet are pelletized to obtain the compound controlled release pellet tablet of nifedipine and atenolol, wherein the controlled release pellet of nifedipine and the controlled release pellet of atenolol are respectively obtained from drug contained core coated with acrylic resin; the weight of coating of the controlled release pellet of nifedipine is added by 10 to 30 percent while the weight of coating of the controlled release pellet of atenolol by 8 to 25 percent; the blank pellet comprises microcrystaline cellulose and one of macrogol 6000, macrogol 4000 and stearic acid or the mixture of one or two of the macrogol 6000, the macrogol 4000 and the stearic acid, wherein the blank pellet takes up 50 to 70 percent of the total weight of the compound controlled release pellet tablet of nifedipine and atenolol.